7 ms·
$5 device tests for breast cancer in under 5 seconds: study
- amelius 3y agoFalse positive / false negative rates?
- soco 3y agoNo larger scale tests yet, they only announced what is basically their current direction or research.
- glitchc 3y ago[flagged]
- m12k 3y ago> Scientists say a new handheld device is capable of testing for breast cancer in less than five seconds using just a small sample of saliva Second sentence in the the linked post
- deleted 3y ago[deleted]
- glitchc 3y agoSo, reading an actual publication [1], all this test does is identify if the patient has the BRCA biomarker for breast cancer. It doesn't actually detect if the patient has breast cancer. The title is misleading, as is your post. [1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249990/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249990/
- DueDilligence 3y ago[dead]
- andyjohnson0 3y agohttps://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/High-sensitivity-saliva-based-biosensor-in https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/Hig... Discusses sensitivity but not accuracy or rates of false positive/negative.
- iwontberude 3y agoUnderlying research about salivary biomarker detection https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566681/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566681/
- zacharyvoase 3y ago> The study is published in the Journal of Vacuum Science & Technology B Dare I ask why?
- rainbowzootsuit 3y agoThin films grown in vacuums are how you get graphene layers and FETs that appear to be the basis of the technology here. Someone with a vacuum deposition system would be the prime candidate to develop a custom thin film to target adsorption of the molecules that they're trying to sense.
- neuronexmachina 3y agoThis part of the study describes what they implemented: >Instead of using the transistors as the sensors, which need to be disposed of after each use, a system with a reusable printed circuit board (PCB) containing a MOSFET and disposable test strips were employed. In this approach, synchronized double-pulses were applied at the gate and drain terminals of the transistor to ensure that the channel charge does not accumulate, and there is no need to reset the drain and gate paths to mitigate the charge accumulation at the gate and drain of the sensing transistor for sequential testing. With the double-pulse approach, it only takes a few seconds to show the result of the test, due to the rapid response of the functionalized test strips and resulting electrical signal output. As an example, the LoD has been demonstrated to reach 10−15 g/ml and the sensitivity to 78/dec for COVID-19 detection. Similar approaches have been used to detect cerebrospinal fluid (CSF), cardiac troponin I, and Zika virus.27–30 > In this work, use of this double-pulse measurement approach to detect HER2 and CA15-3 in saliva samples collected from healthy volunteers and breast cancer patients was investigated. The voltage output responses of the transistor correlated to the HER2 and CA15-3 concentrations, detection limits, and sensing sensitivity were determined.
- moi2388 3y agoBecause much like vacuums, cancer sucks
- 3y ago
- andrew_eu 3y agoThe publication is linked in the article [0]. Even if it's only for HER2 patients, even if it's only useful as a first-pass test, this is still great news. The experimental design seems very small scale though. 17 cancer positive samples (of which only 1 was HER2 positive), 4 control. Since the strips are focused on HER2 detection I read this as "in 1 out of 1 samples, our test detected HER2 overexpression" but maybe I misread it. [0] https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/High-sensitivity-saliva-based-biosensor-in https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/Hig...
- e63f67dd-065b 3y agoPress release: https://publishing.aip.org/publications/latest-content/would-you-prefer-a-mammogram-mri-or-saliva-on-a-test-strip/ https://publishing.aip.org/publications/latest-content/would... Actual publication: https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/High-sensitivity-saliva-based-biosensor-in https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/Hig... Experiment size is literally N=21, with 4 healthy participants, 3 in-situ breast cancers, and 14 invasive breast cancers. N=21 might as well be useless in my opinion. You can't draw any meaningful conclusions about statistical power of this test; if your priors were 10% for breast cancer, after taking this test, your posterior probably remains unchanged.
- causal 3y agoYah headline jumping the gun a bit, but hopefully this motivates funding to get a bigger study / refine the technique.
- deleted 3y ago[deleted]
- pvaldes 3y ago> We tried it with 21 people The new Theranos is here again
- dheera 3y agoNo, not at all. Polar opposites. Theranos was actual lies. TFA is just being honest about a low sample size.
- pvaldes 3y agoIf somebody claims: our device "accurately tests", and we discover later that "In fact the tests hadn't been done still" (at a meaningful way), It should be taken as a red flag. Specially when it came in the same package with "to make lots of tests would be really cheap" (but for some reason they didn't tried it). Maybe be a great, honest work, brilliant step?. Yes. But please don't claim that your model is reproducible if you didn't ever tried seriously to reproduce it first. What if the results are just a random effect?. What if the test says just positive most of the time? The test negative response has been tested in a control group of 4 people? This is 20 bucks well spent. --At this moment-- isn't different than other thousand projects that seemed too good to be true, took the money and soon vanished. I hope to be wrong.
- shelkie 3y agoCool how they're using BNC connectors and ICs from the 1980's /s
- Ginger-Pickles 3y agoFirst standout thing I noticed is the “patern generator” array of DIPs - admittedly without having dived into the paper, any answers from the hive mind what they’re doing?
- joezydeco 3y agoI was focusing more on the "current to frequency" stage, which looks like an empty IC socket. As is the "pulse width counting" stage just a bunch of header pins? I mean yeah, I get it, it's a prototype and a finished product will be on a $2 ASIC to drive the correct signals and etc. But I'm not up to speed on affinity sensors vs. traditional ELISA tech so <internet shrug>.
- lambdaone 3y agoNothing jumps out at me as being fishy here. There's what appears to be a small device mounted in the middle of that empty socket. It's also possible some of the rest of the pins on the socket are being used as test points. A circuit diagram would have be good to have here.
- dtgriscom 3y agoYeah; it's a bit strange to label a single MOSFET...
- shelkie 3y agoBreast cancer is a terrible disease, and I don't mean to be a downer but my BS detector is screaming on this one. I'd give the device image a pass if were just a journalist grabbing a stock PCB image, but that doesn't seem to be the case here. Anyone with even a trivial knowledge of electronics would be amused by the callouts. And all for just $5? After Theranos I guess I'm a bit sceptical of claims such as this.
- Aachen 3y ago> employs paper test strips coated with specific antibodies. These antibodies interact with cancer biomarkers [from] a drop of saliva > “[...] cost-effective, with the test strip costing just a few cents and the reusable circuit board priced at $5,” Wan says. That is cool: the 5$ isn't even the cost of the test, it's the one-time cost of your lab equipment. Of course, per sibling comments, the efficacy has yet to be seen, but even a few percent more early detections due to frequent testing would be a win
- iamthepieman 3y ago"but even a few percent more early detections due to frequent testing would be a win" This is not the current medical thought on early screenings for various cancers. It used to be and I was confused about it until very recently. Indeed the medical community is still wrestling with the issue of screening harms. The consensus is shifting that screening should only be done if there is an existing condition or symptom or family history. https://www.cancer.gov/news-events/cancer-currents-blog/2022/cancer-screening-guidelines-lack-harms https://www.cancer.gov/news-events/cancer-currents-blog/2022...
- bluGill 3y agoThat depends on how harmful the screening is, how harmful treatment is, how harmful the disease is, how well the test works, and how common the disease is. (probably more that I'm not aware of) Most cancer treatments are really nasty. Thus false positives are really bad: you destroy someone's quality of life. The earlier cancer is discovered the better chance that we can use a less harmful treatment (if only because of smaller dose of the harmful drugs) The current breast cancer screening is an xray - which itself causes cancer (about 1 in 3000 cases of breast cancer discovered by xray wouldn't have got breast cancer in the first place without the screening - the screening is still wroth doing if you are at risk, but don't do it if you are not at risk). Breast cancer can be deadly, but if caught early it is easy to treat (normally). The medical concern generally isn't should we test all women for breast cancer, but when do we start testing and how often should we test. If this test is safer than an xray and sensitive enough it can be useful. Avoiding current breast cancer tests is good.
- deweller 3y agoWould a US company have enough financial incentive to front the cost of FDA approval in the US? I'm guessing it is expensive to jump through all of the hoops. Without a patent, why would a company pay for this?
- deleted 3y ago[deleted]
- adam_arthur 3y agoUsually with medical innovations, the idea is patented and the product is sold well above cost of production. e.g. this $5 device could be sold for $100 each... large profit margin. If there is no patent, and no in-place infrastructure already producing the device, then yes, it's unlikely to see rapid scale up by manufacturers. Though if it's really that cheap to produce, I'm sure it will come onto market in some form (whether through charitable foundations or otherwise). All assuming that the device is actually as efficacious as the study implies (with a small sample size).
- zdragnar 3y agoAs a non-invasive diagnostic equipment, let us say it is akin to a pregnancy test, or a creatine in urine test. That puts it in Class 1, and may be exempt from a lot of the hoops a medicine would go through. There are a little over 6,100 hospitals in the US at any given time. That means roughly $30,000 in cost to produce to provide every hospital with one, using the cheapest of cheapest parts. Presumably, you'd want higher end components and things like a shell casing to protect from spills, static, etc. maybe the cost is $120k. You could sell these for $100 each, and maybe make $5 million. That's a decent amount of money for a tiny business, but a pittance for even a small business that needs to pay salaries, lawyers, etc. In reality, they'd probably go for much more- let's say $10k each, plus $100 for each test strip. Still easily in range for the budget of most US hospitals. The real question is, if breast cancer is suspected, is this test any better than imaging using equipment the hospital already has? Can it detect all types, or the degree that it is progressing? I suspect the utility in a clinical setting is not high enough to really change clinical practices any.
- 3y ago
- iandanforth 3y agoFigures 3 and 5 from the paper (https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/High-sensitivity-saliva-based-biosensor-in https://pubs.aip.org/avs/jvb/article/42/2/023202/3262988/Hig...) have overlap between all the groups. The same measured output could have come from any of the non-cancer, or known-cancer, participants. While the means of these groups look nicely separable, that overlap means there will be significant false positives or false negatives. So I'd label the studyfinds headline of this being 'accurate' to be false.
- ImageXav 3y agoNot at all. The model is quite accurate. In fact, with the distribution of samples that they have a model that predicts all cases as having cancer would also be very accurate. It would get 17/21 predictions right. The model lacks precision. I suspect that even with a fairly high cut off point the model would still produce a bevvy of false positive predictions due to that. It might still be useful as a screening step if they can increase the sensitivity further, but you would still rely upon further tests to get a true diagnosis.
- dmoy 3y agoSure we can be technically more surgical in our terminology, but GP is addressing the usage of 'accuracy' in the news headline. In that context, 'accuracy' is kinda a catchall term for both accuracy and precision.
- ImageXav 3y agoIt's a bit difficult to say, isn't it? The headline is using the term accuracy correctly, the reader might be ascribing the meaning you are to it, especially if they are non technical. As was the parent comment. My goal in pointing out the difference was not to be snarky. It was to point out the very real statistical consequences. Any model can be accurate on a sufficiently biased dataset, but what matters once a screening test hits the real world are the precision (positive predictive value) and negative predictive value. These are the hurdles that the test will have to pass to see widespread adoption.
- m3kw9 3y agoIf it’s any good it will filter thru to a doctor near you otherwise, it all sounds nice
- shermantanktop 3y agoReally? Will the $5 Arduino people woo the doctor near you with golf trips? Will they strong arm HMOs to cover the cost? Will they carpetbomb the airwaves telling consumers to “ask their doctor?” Will they defeat the army of marketers and salespeople with entrenched competing tech? This device may be total crap, I don’t know, but “trust the system” isn’t a great way to navigate the American medical system. Other countries have it better, or at least different.
- s1artibartfast 3y agoDoctors do gravitate towards effective tests and medicines, and insurance plans are interest in cheaper alternatives. There is a lot that could be improved about the US medical system, but Nobody has to bribe doctors and insurance to sell tongue depressors.
- shermantanktop 3y agoI would bet someone out there has attempted to come up with a high-margin tongue depressor with fancy built-in features. But the plain wooden stick is already entrenched and obviously effective (for depressing tongues). This is the opposite. If the state of the art was a fancy tongue manipulation machine that cost $30k, used licensed consumables billed at $100/patient, and did a bunch of non-essential things that doctors found convenient once in a while, would someone selling a box of sticks get anywhere?
- loeg 3y agoSomeone has to actually commercialize this and get it approved and it will cost far more than $5. As part of that they have to demonstrate that it is, ya know, useful (vs existing methods).
- yakito 3y agoAs a reference. Currently an MRI scan can go from $400-$2000 (mostly covered by insurance) https://scan.com/body-parts/breast https://scan.com/body-parts/breast An MRI machine cost arounds $350.000 on average. https://www.blockimaging.com https://www.blockimaging.com
- ImageXav 3y agoA device such as this would never replace an MRI scan. The information provided is for screening purposes, at best. Also, diagnosis would typically be done using a mammography. The cost of such a scan is lower - around $100[0]. [0]https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142190/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142190/
- bluGill 3y agoIt doesn't have to replace it in all cases. If it can give a good indication that we don't have to do a MRI that is already a good thing.
- ImageXav 3y agoThat's right, that's typically what is meant by screening purposes [0], apologies if it wasn't clear. [0] https://www.nhs.uk/conditions/nhs-screening/ https://www.nhs.uk/conditions/nhs-screening/
- Dylan16807 3y agoThe unclear part was more the phrase "would never replace an MRI scan". But it's clear now.
- sparklingmango 3y agoDiagnosis is done via biopsy.
- ImageXav 3y ago
- alhirzel 3y agoThe "press release" looks more like a final report for a microcontroller applications class than an actual press release.
- SV_BubbleTime 3y agoDiagram aside. The thirty through hole parts made me the think the same thing.
- Linda231 3y ago[dead]
- moi2388 3y agoIf I look at figure 3 and 5 I immediately see quite a bit of overlap between the readings of the different groups..
- masto 3y agoSeems like this was originally built for SARS-CoV-2. Here's the paper from 2021: https://pubs.aip.org/avs/jvb/article-abstract/39/3/033202/591511/Fast-SARS-CoV-2-virus-detection-using-disposable https://pubs.aip.org/avs/jvb/article-abstract/39/3/033202/59... and then in 2022 for detecting oral cancer: https://pubs.aip.org/avs/jvb/article/41/1/013201/2866658/High-sensitivity-CIP2A-detection-for-oral-cancer https://pubs.aip.org/avs/jvb/article/41/1/013201/2866658/Hig...
- asdefghyk 3y agoThe PCB picture above the words "...The printed circuit board used in the saliva-based biosensor,..." makes me think the article is a scam. As a electronics engineer the word labels seem to be not especially relevant to the invention. Who makes boards with lots DIP chips?
- SV_BubbleTime 3y agoYea, I was really curious about those. I mean… even if we were talking some special hardware, that’s still PLC territory. My reading was this isn’t $5, but could be made to be $5. This is clearly a prototype.
- amelius 3y agoGiven that only one such device is needed per (say) 100-500 people, I think the device can probably cost a lot more and still be as affordable and effective.
- biomcgary 3y agoUsing the performance in the paper, the false positive rate means the current test in clinically useless (due to harm from screening and follow-up). Refining the test requires improving the selection of biomarkers and antibodies, not the hardware (which looks great).
- SV_BubbleTime 3y agoNo offense, but as someone that makes hardware devices, that hardware does not look great. It looks the very opposite of great. Through hole DIP array? This is a prototype and it makes me skeptical of the whole thing. There is nothing a single $5 FPGA couldn’t do. So why not start there? I suspect because the people that made this doesn’t know electronics or programming well - but then also didn’t find someone that did. This was put together the way long way, and it’s strange to me.
- DoreenMichele 3y agoThe biosensor, a collaborative development by the University of Florida and National Yang Ming Chiao Tung University in Taiwan, employs paper test strips coated with specific antibodies. These antibodies interact with cancer biomarkers targeted in the test. Upon placing a drop of saliva on the strip, electrical pulses are sent to contact points on the biosensor device. This process leads to the binding of biomarkers to antibodies, resulting in a measurable change in the output signal. This change is then converted into digital data, indicating the biomarker’s presence. It tests for biomarkers in the saliva. Possibly not outright crazy charlatan territory. Could certainly use a larger sample size though, especially given that one of its bragging points is "fast and cheap!"
- adamredwoods 3y ago>> HER2 and/or CA15-3 in serum are essential biomarkers used in breast cancer diagnosis. This is WRONG, it is used as an indicator, NOT a diagnosis. In fact, I have personal experience that CA15-3 is not always in indicator of anything. You first measure a baseline, and use it for reference. Also there's no HER2 expression in TNBC. Can this be used for possible early detection? Maybe, but it will not be an exact science.
- vpribish 3y agoclickbait misleading headline from a garbage-tier SEO-mill website. flag this and ban the website
- redder23 3y ago$0 device tests for breast cancer in under 5 seconds: its called a hand.
- F51user 3y agoLargely BS. 1) These are not clinical biomarkers used for detection of cancer now, and in fact, they are known NOT to be clinical biomarkers useful for detecting cancer. 2) This is a publication focusing on the device/method, not the clinical application. It is published in a journal of vacuum science, not a cancer biology or medical journal. 3) There are several inaccurate things in the paper, one being that they state that current technology requires 1-2 weeks to measure either biomarker. Wrong, clinical tests exist today that can perform those immunoassays in minutes on large automated analyzers. 4) This isn't fraud, it's just a really typically overhyped report of a novel device/meausrement strategy (and it's not that novel) that targets a biomarker that has a role in cancer, and then some mass media picks it up and says that they have "the test for cancer". This happens all the time. 5) This should maybe be considered a proof of concept about the electronics of their detection strategy, since the immunoassay component is known (immunoassays to both biomarkers are not only published, but commercialized) and the clinical use of the biomarkers is not at all diagnostic for cancer or useful for screening.
- deleted 3y ago[deleted]
- susiecambria 3y agoI could not assess the validity of this paper if my life depended on it. But this is what I do know: Given that the University of Florida is a public institution and the governor of the state is anti-science and promotes anti-science policies and practices, my immediate reaction to this paper’s news is negative. Reasonable? Probably not. I can’t be the only one who would react in this way. This matters for two reasons. First, each of us has limited time and capacity to care about things, to investigate them more. Second, if we don’t recognize our biases, we may ignore important and useful information.